146 related articles for article (PubMed ID: 37324544)
1. Lurbinectedin, a DNA minor groove inhibitor for neuroendocrine neoplasms beyond small cell lung cancer.
Bhamidipati D; Subbiah V
Oncoscience; 2023; 10():22-23. PubMed ID: 37324544
[No Abstract] [Full Text] [Related]
2. Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC).
Liguori NR; Sanchez Sevilla Uruchurtu A; Zhang L; Abbas AE; Lee YS; Zhou L; Azzoli CG; El-Deiry WS
Am J Cancer Res; 2022; 12(2):729-743. PubMed ID: 35261798
[TBL] [Abstract][Full Text] [Related]
3. Lurbinectedin in the treatment of relapsed small cell lung cancer.
Baena J; Modrego A; Zeaiter A; Kahatt C; Alfaro V; Jimenez-Aguilar E; Mazarico JM; Paz-Ares L
Future Oncol; 2021 Jun; 17(18):2279-2289. PubMed ID: 33736462
[TBL] [Abstract][Full Text] [Related]
4. Lurbinectedin for the treatment of small cell lung cancer.
Li L; Zou C; Dong S; Wu ZX; Ashby CR; Chen ZS; Qiu C
Drugs Today (Barc); 2021 Jun; 57(6):377-385. PubMed ID: 34151904
[TBL] [Abstract][Full Text] [Related]
5. Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients.
Aviles P; Altares R; van Andel L; Lubomirov R; Fudio S; Rosing H; Márquez Del Pino FM; Tibben MM; Benedit G; Nan-Offeringa L; Luepke Estefan XE; Francesch A; Zeaiter A; Cuevas C; Schellens JHM; Beijnen JH
Drug Metab Dispos; 2022 Apr; 50(4):327-340. PubMed ID: 35042701
[TBL] [Abstract][Full Text] [Related]
6. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin.
Matsui S; Haruki T; Oshima Y; Kidokoro Y; Sakabe T; Umekita Y; Nakamura H
Thorac Cancer; 2022 Apr; 13(8):1184-1192. PubMed ID: 35278040
[TBL] [Abstract][Full Text] [Related]
7. Second-line lurbinectedin as a new treatment option for small-cell lung cancer: Preliminary results in real-clinical practice.
Toublanc AC; Guecamburu M; Veillon R; Rosellini P; Girodet PO; Zysman M
Thorac Cancer; 2022 Aug; 13(15):2248-2252. PubMed ID: 35715960
[TBL] [Abstract][Full Text] [Related]
8. SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer.
Kundu K; Cardnell RJ; Zhang B; Shen L; Stewart CA; Ramkumar K; Cargill KR; Wang J; Gay CM; Byers LA
Transl Lung Cancer Res; 2021 Nov; 10(11):4095-4105. PubMed ID: 35004241
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Small Cell Lung Cancer with Lurbinectedin: A Review.
Rajput PS; Khan SR; Singh P; Chawla PA
Anticancer Agents Med Chem; 2022; 22(5):812-820. PubMed ID: 34229593
[TBL] [Abstract][Full Text] [Related]
10. Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer.
Vidal A; Muñoz C; Guillén MJ; Moretó J; Puertas S; Martínez-Iniesta M; Figueras A; Padullés L; García-Rodriguez FJ; Berdiel-Acer M; Pujana MA; Salazar R; Gil-Martin M; Martí L; Ponce J; Molleví DG; Capella G; Condom E; Viñals F; Huertas D; Cuevas C; Esteller M; Avilés P; Villanueva A
Clin Cancer Res; 2012 Oct; 18(19):5399-411. PubMed ID: 22896654
[TBL] [Abstract][Full Text] [Related]
11. Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer.
Kepp O; Zitvogel L; Kroemer G
Oncoimmunology; 2020 Jul; 9(1):1795995. PubMed ID: 32923159
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors.
Calvo E; Sessa C; Harada G; de Miguel M; Kahatt C; Luepke-Estefan XE; Siguero M; Fernandez-Teruel C; Cullell-Young M; Stathis A; Drilon A
Invest New Drugs; 2022 Dec; 40(6):1263-1273. PubMed ID: 35947247
[TBL] [Abstract][Full Text] [Related]
13. Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma.
Dumoulin DW; Cantini L; Cornelissen R; Vink M; Klaase L; Slooff K; Tebayna N; Mankor JM; Baart SJ; Hendriks R; Dingemans AC; Willemsen M; Aerts JGJV
Eur J Cancer; 2022 Sep; 172():357-366. PubMed ID: 35834843
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives.
Musacchio L; Cicala CM; Salutari V; Camarda F; Carbone MV; Ghizzoni V; Giudice E; Nero C; Perri MT; Ricci C; Tronconi F; Scambia G; Lorusso D
Front Oncol; 2022; 12():831612. PubMed ID: 35280728
[TBL] [Abstract][Full Text] [Related]
15. An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer.
Patel S; Petty WJ; Sands JM
Ther Adv Med Oncol; 2021; 13():17588359211020529. PubMed ID: 34104228
[TBL] [Abstract][Full Text] [Related]
16. Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma.
Gadducci A; Cosio S
Front Oncol; 2022; 12():914342. PubMed ID: 36408147
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.
Benton CB; Chien KS; Tefferi A; Rodriguez J; Ravandi F; Daver N; Jabbour E; Jain N; Alvarado Y; Kwari M; Pierce S; Maiti A; Hornbaker M; Santos MA; Martinez S; Siguero M; Zblewski D; Al-Kali A; Hogan WJ; Kantarjian H; Pardanani A; Garcia-Manero G
Hematol Oncol; 2019 Feb; 37(1):96-102. PubMed ID: 30153704
[TBL] [Abstract][Full Text] [Related]
18. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
Aix SP; Ciuleanu TE; Navarro A; Cousin S; Bonanno L; Smit EF; Chiappori A; Olmedo ME; Horvath I; Grohé C; Farago AF; López-Vilariño JA; Cullell-Young M; Nieto A; Vasco N; Gómez J; Kahatt C; Zeaiter A; Carcereny E; Roubec J; Syrigos K; Lo G; Barneto I; Pope A; Sánchez A; Kattan J; Zarogoulidis K; Waller CF; Bischoff H; Juan-Vidal O; Reinmuth N; Dómine M; Paz-Ares L
Lancet Respir Med; 2023 Jan; 11(1):74-86. PubMed ID: 36252599
[TBL] [Abstract][Full Text] [Related]
19. Lurbinectedin: A New Treatment Option for Relapsed/Refractory Small-Cell Lung Cancer.
Shinn LT; Vo KA; Reeves DJ
Ann Pharmacother; 2021 Sep; 55(9):1172-1179. PubMed ID: 33348988
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis.
Boyne DJ; Dawe DE; Shakir H; Joe-Uzuegbu O; Farah E; Pabani A; Baratta C; Brenner DR; Cheung WY
Target Oncol; 2023 Sep; 18(5):697-705. PubMed ID: 37656263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
